Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.

Abstract:

:Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown promising response rates in relapsed and newly diagnosed MM, and bortezomib has recently been reported to inhibit OCLs. We here investigated the effect of lenalidomide on OCL formation and osteoclastogenesis in comparison with bortezomib. Both drugs decreased alpha V beta 3-integrin, tartrate-resistant acid phosphatase-positive cells and bone resorption on dentin disks. In addition, both agents decreased receptor activator of nuclear factor-kappaB ligand (RANKL) secretion of bone marrow stromal cells (BMSCs) derived from MM patients. We identified PU.1 and pERK as major targets of lenalidomide, and nuclear factor of activated T cells of bortezomib, resulting in inhibition of osteoclastogenesis. Furthermore, downregulation of cathepsin K, essential for resorption of the bone collagen matrix, was observed. We demonstrated a significant decrease of growth and survival factors including macrophage inflammatory protein-alpha, B-cell activating factor and a proliferation-inducing ligand. Importantly, in serum from MM patients treated with lenalidomide, the essential bone-remodeling factor RANKL, as well as the RANKL/OPG ratio, were significantly reduced, whereas osteoprotegerin (OPG) was increased. We conclude that both agents specifically target key factors in osteoclastogenesis, and could directly affect the MM-OCL-BMSCs activation loop in osteolytic bone disease.

journal_name

Leukemia

journal_title

Leukemia

authors

Breitkreutz I,Raab MS,Vallet S,Hideshima T,Raje N,Mitsiades C,Chauhan D,Okawa Y,Munshi NC,Richardson PG,Anderson KC

doi

10.1038/leu.2008.174

subject

Has Abstract

pub_date

2008-10-01 00:00:00

pages

1925-32

issue

10

eissn

0887-6924

issn

1476-5551

pii

leu2008174

journal_volume

22

pub_type

杂志文章,随机对照试验

相关文献

LEUKEMIA文献大全
  • B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

    abstract::Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there i...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-0734-z

    authors: Shah N,Chari A,Scott E,Mezzi K,Usmani SZ

    更新日期:2020-04-01 00:00:00

  • Reconstitution of peripheral blood lymphocyte subsets in the long-term disease-free survivors of patients with acute myeloblastic leukemia.

    abstract::The number of long-term survivors of patients with acute myeloblastic leukemia (AML) has increased as a result of the progress of chemotherapy. We examined the recovery of peripheral blood lymphocytes (PBL) subset after chemotherapy to clarify the reconstitution of the immune system in AML. Thirty patients with AML in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400891

    authors: Ohnishi K,Yamanishi H,Naito K,Utsumi M,Yokomaku S,Hirabayashi N,Ohno R

    更新日期:1998-01-01 00:00:00

  • The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate.

    abstract::Toll-like receptors (TLRs) constitute a family of nonpolymorphic receptors that are devoted to pathogen recognition. In this work, we have explored the impact of TLR ligands (TLR-L) on human hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). We show that HSCs and HPCs have a comparable pattern ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.155

    authors: De Luca K,Frances-Duvert V,Asensio MJ,Ihsani R,Debien E,Taillardet M,Verhoeyen E,Bella C,Lantheaume S,Genestier L,Defrance T

    更新日期:2009-11-01 00:00:00

  • Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

    abstract::Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the effic...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2009.111

    authors: Giles FJ,O'Dwyer M,Swords R

    更新日期:2009-10-01 00:00:00

  • bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient.

    abstract::Using the polymerase chain reaction and Southern blot analysis the expression was detected of a bcr-abl mRNA lacking abl exon a2. This was due to a corresponding unusual localization of the breakpoint in the c-abl gene and was seen in a patient with Philadelphia (Ph) chromosome positive chronic myelogeneous leukemia i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: van der Plas DC,Soekarman D,van Gent AM,Grosveld G,Hagemeijer A

    更新日期:1991-06-01 00:00:00

  • Distribution of IL-6 receptors on murine hemopoietic and lymphoid cells and the anomalous action of IL-6 in stimulating granulocytic proliferation.

    abstract::Autoradiographic analysis of the binding of radiolabeled murine IL-6 to murine cells revealed that blast cells, megakaryocytic and monocytic cells in the marrow expressed receptors but not erythroid, eosinophilic or neutrophilic granulocytic cells. In the thymus, spleen and lymph nodes, most cells expressing receptors...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: McKinstry W,Metcalf D,Li CL

    更新日期:1994-10-01 00:00:00

  • Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells.

    abstract::Suppression of c-myc expression is observed during induced differentiation of several myeloid cell lines and it has been attributed to the cell growth arrest that accompanies terminal differentiation. To dissect the role of c-Myc in the proliferation-differentiation switch we have studied c-myc expression in K562 cell...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gómez-Casares MT,Delgado MD,Lerga A,Crespo P,Quincoces AF,Richard C,León J

    更新日期:1993-11-01 00:00:00

  • Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.

    abstract::We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfav...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.234

    authors: Caramazza D,Begna KH,Gangat N,Vaidya R,Siragusa S,Van Dyke DL,Hanson C,Pardanani A,Tefferi A

    更新日期:2011-01-01 00:00:00

  • The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study.

    abstract::In this open-label randomized clinical trial, HLA-identical sibling-matched hematopoietic stem cells (HSC) were transplanted (non-MSCs group, n=15) or cotransplanted with mesenchymal stem cells (MSCs) (MSCs group, n=10) in hematologic malignancy patients. The median number of MSCs infused was 3.4 x 10(5) kg(-1) (range...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/sj.leu.2405090

    authors: Ning H,Yang F,Jiang M,Hu L,Feng K,Zhang J,Yu Z,Li B,Xu C,Li Y,Wang J,Hu J,Lou X,Chen H

    更新日期:2008-03-01 00:00:00

  • Rapid and reliable detection of N-ras mutations in acute lymphoblastic leukemia by melting curve analysis using LightCycler technology.

    abstract::We applied a new strategy for the detection of N-ras gene mutations based on LightCycler technology. We designed two sets of amplimers and internal hybridization probes representing N-ras codons 12/13 and codon 61, respectively. Genomic DNAs from 134 childhood acute lymphoblastic leukemia (ALL) patients (83 common ALL...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401645

    authors: Nakao M,Janssen JW,Seriu T,Bartram CR

    更新日期:2000-02-01 00:00:00

  • Current status of reduced-intensity allogeneic stem cell transplantation using alternative donors.

    abstract::The optimal donor for a patient undergoing reduced-intensity stem cell transplantation remains a human leukocyte antigen (HLA)-matched relative. Alternative donors such as matched unrelated donors (MUDs), mismatched related donors (haploidentical), or unrelated umbilical cord blood (UCB) units have emerged as options ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404932

    authors: Chen YB,Spitzer TR

    更新日期:2008-01-01 00:00:00

  • T cell receptor alpha mRNA transcription in T-lymphoblastic transformation of chronic myelocytic leukemia.

    abstract::Analysis at the DNA and RNA level revealed a mature genetic marker profile in a case of T type blast crisis of chronic myelocytic leukemia. T cell receptor beta chain gene rearrangement as well as T cell receptor alpha mRNA transcription was demonstrated in blasts of the malignant clone. Corresponding findings were ob...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Valent P,Bartram CR,Radaszkiewicz T,Hinterberger W,Lechner K,Bettelheim P

    更新日期:1988-03-01 00:00:00

  • The MLL recombinome of acute leukemias in 2017.

    abstract::Chromosomal rearrangements of the human MLL/KMT2A gene are associated with infant, pediatric, adult and therapy-induced acute leukemias. Here we present the data obtained from 2345 acute leukemia patients. Genomic breakpoints within the MLL gene and the involved translocation partner genes (TPGs) were determined and 1...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.213

    authors: Meyer C,Burmeister T,Gröger D,Tsaur G,Fechina L,Renneville A,Sutton R,Venn NC,Emerenciano M,Pombo-de-Oliveira MS,Barbieri Blunck C,Almeida Lopes B,Zuna J,Trka J,Ballerini P,Lapillonne H,De Braekeleer M,Cazzaniga G,Cor

    更新日期:2018-02-01 00:00:00

  • Decrease of memory T helper cells (CD4+ CD45R0+) in hairy cell leukemia.

    abstract::Patients with hairy cell leukemia (HCL) are prone to opportunistic infections, which suggests an impaired T-cell functioning. To investigate a possible mechanism of such an impairment, we determined the numbers of naive and memory T cells by measuring the expression of CD45R0 on CD4+ and CD8+ T cells in 23 HCL patient...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: van der Horst FA,van der Marel A,den Ottolander GJ,Kluin-Nelemans HC

    更新日期:1993-01-01 00:00:00

  • Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.

    abstract::Sequential analysis of chimerism after allogeneic blood stem cell transplantation (BSCT) has been shown to be predictive for graft failure and relapse. We have explored the impact of a novel approach for the quantitative determination of chimerism using a commercial PCR assay with multiplex amplification of nine STR-l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401953

    authors: Thiede C,Bornhäuser M,Oelschlägel U,Brendel C,Leo R,Daxberger H,Mohr B,Florek M,Kroschinsky F,Geissler G,Naumann R,Ritter M,Prange-Krex G,Lion T,Neubauer A,Ehninger G

    更新日期:2001-02-01 00:00:00

  • Interstitial telomere repeats in translocations of hematopoietic disorders.

    abstract::Cytogenetic and fluorescence in situ hybridization studies have shown the presence of telomeric repeats in translocation present in three patients with hematopoietic malignancies. One had jumping translocations, involving 1q12 and 2q, 16p, and 19q. These sequences were detected by FISH only in derivative chromosomes t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401876

    authors: Busson Le Coniat M,Brizard F,Smadja NV,Maarek O,Der Sarkissian H,Berger R

    更新日期:2000-09-01 00:00:00

  • CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.

    abstract::The presence of rare malignant stem cells supplying a hierarchy of malignant cells has recently been reported. In human acute myelogenous leukemia (AML), the leukemia stem cells (LSCs) have been phenotypically restricted within the CD34+CD38- fraction. To understand the origin of malignant cells in primary human B-pre...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.83

    authors: Kong Y,Yoshida S,Saito Y,Doi T,Nagatoshi Y,Fukata M,Saito N,Yang SM,Iwamoto C,Okamura J,Liu KY,Huang XJ,Lu DP,Shultz LD,Harada M,Ishikawa F

    更新日期:2008-06-01 00:00:00

  • Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

    abstract::Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2016.299

    authors: Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

    更新日期:2017-04-01 00:00:00

  • Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease.

    abstract::In all, 17 consecutive patients in hematological complete remission (HCR) of acute promyelocytic leukemia (APL) received allogeneic stem cell transplantation (SCT) from an HLA-identical sibling and were monitored by reverse transcriptase polymerase chain reaction of PML/RARalpha prior and after transplant. Median age ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403078

    authors: Lo-Coco F,Romano A,Mengarelli A,Diverio D,Iori AP,Moleti ML,De Santis S,Cerretti R,Mandelli F,Arcese W

    更新日期:2003-10-01 00:00:00

  • Localization of the chromosome 15 breakpoints and expression of multiple PML-RAR alpha transcripts in acute promyelocytic leukemia: a study of 28 Chinese patients.

    abstract::Translocation (15;17)(q22;q12-q21) is a chromosome aberration specifically found in acute promyelocytic leukemia (APL), that generates a chimeric gene between the promyelocytic leukemia (PML) gene on chromosome 15 and the retinoic acid receptor alpha (RARA) gene, on chromosome 17. In the course of molecular investigat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Geng JP,Tong JH,Dong S,Wang ZY,Chen SJ,Chen Z,Zelent A,Berger R,Larsen CJ

    更新日期:1993-01-01 00:00:00

  • DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups.

    abstract::We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in the form of gains or l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404653

    authors: Suela J,Alvarez S,Cifuentes F,Largo C,Ferreira BI,Blesa D,Ardanaz M,García R,Marquez JA,Odero MD,Calasanz MJ,Cigudosa JC

    更新日期:2007-06-01 00:00:00

  • The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.

    abstract::We previously reported a strong IL4I1 gene expression in primary mediastinal B-cell lymphoma (PMBL) and recently identified the protein as a secreted L-phenylalanine oxidase, physiologically expressed by myeloid cells, which inhibits T-cell proliferation in vitro. Here, we analyzed the pattern of IL4I1 protein express...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.380

    authors: Carbonnelle-Puscian A,Copie-Bergman C,Baia M,Martin-Garcia N,Allory Y,Haioun C,Crémades A,Abd-Alsamad I,Farcet JP,Gaulard P,Castellano F,Molinier-Frenkel V

    更新日期:2009-05-01 00:00:00

  • Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes.

    abstract::Transplantation of normal and malignant human hematopoietic cells into severe combined immunodeficient (SCID) mice allows for evaluation of long-term growth abilities of these cells and provides a preclinical model for therapeutic interventions. However, large numbers of cells are required for successful engraftment i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400694

    authors: Terpstra W,Leenen PJ,van den Bos C,Prins A,Loenen WA,Verstegen MM,van Wyngaardt S,van Rooijen N,Wognum AW,Wagemaker G,Wielenga JJ,Löwenberg B

    更新日期:1997-07-01 00:00:00

  • JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation.

    abstract::The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.114

    authors: Zhan H,Ma Y,Lin CH,Kaushansky K

    更新日期:2016-12-01 00:00:00

  • PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia.

    abstract::Chronic lymphocytic leukemia (CLL) cells with aggressive clinical properties express lipoprotein lipase (LPL), which generates activating ligands for the nuclear receptor peroxisome proliferator activated receptor (PPAR)α and allows fatty acids to be used as fuel. However, the role of PPARα in CLL is unclear. PPARα wa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.329

    authors: Spaner DE,Lee E,Shi Y,Wen F,Li Y,Tung S,McCaw L,Wong K,Gary-Gouy H,Dalloul A,Ceddia R,Gorzcynski R

    更新日期:2013-04-01 00:00:00

  • The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype.

    abstract::To examine whether the percentage of myeloperoxidase (MPO)-positive blast cells is useful as a prognostic factor for acute myeloid leukemia (AML), cytochemical analysis of MPO was performed in 491 patients who were registered to the Japan Adult Leukemia Study Group-AML92 study. Patients were divided into two using the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403010

    authors: Matsuo T,Kuriyama K,Miyazaki Y,Yoshida S,Tomonaga M,Emi N,Kobayashi T,Miyawaki S,Matsushima T,Shinagawa K,Honda S,Ohno R,Japan Adult Leukemia Study Group.

    更新日期:2003-08-01 00:00:00

  • Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma.

    abstract::In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32 lenalidomide-refractory multiple myeloma (MM) patients; 31 were evaluable for response and toxicity. At dose level 1 (DL1, 3 mg Ixa), 1/3 patients experienced grade ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-018-0038-8

    authors: Krishnan A,Kapoor P,Palmer JM,Tsai NC,Kumar S,Lonial S,Htut M,Karanes C,Nathwani N,Rosenzweig M,Sahebi F,Somlo G,Duarte L,Sanchez JF,Auclair D,Forman SJ,Berdeja JG

    更新日期:2018-07-01 00:00:00

  • Identification of T-cell epitopes for cancer immunotherapy.

    abstract::The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an optimal immunostimulatory context of the therapy and the proper selection with respect to quality and quantity of the targeted tumor-associated antigens (TAA), and, more precisely, the T-cell epitopes contained in these tumor proteins. Our...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404787

    authors: Kessler JH,Melief CJ

    更新日期:2007-09-01 00:00:00

  • Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) - a report of the Children's Cancer Group.

    abstract::Infants less than 1 year of age at diagnosis of acute lymphoblastic leukemia (ALL) have a poor prognosis, which has been attributed primarily to a breakpoint in chromosomal band 11q23 or the MLL gene. Most infants with an 11q23 breakpoint have a t(4;11)(q21 ;q23). We studied the cytogenetics of the leukemia cells of 5...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401413

    authors: Heerema NA,Sather HN,Ge J,Arthur DC,Hilden JM,Trigg ME,Reaman GH

    更新日期:1999-05-01 00:00:00

  • Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study.

    abstract::Chronic graft-versus-host disease (GVHD) remains a serious complication after allogeneic hematopoietic stem cell transplantation (HCT). In 2005 the National Institutes of Health (NIH) established new criteria for chronic GVHD based on retrospective data and expert recommendations. We prospectively evaluated the incide...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.257

    authors: Kuzmina Z,Eder S,Böhm A,Pernicka E,Vormittag L,Kalhs P,Petkov V,Stary G,Nepp J,Knobler R,Just U,Krenn K,Worel N,Greinix HT

    更新日期:2012-04-01 00:00:00